- Home
- FC vs PLX Comparison
FC vs PLX Comparison
Compare FC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FC | PLX |
|---|---|---|
| Founded | 1983 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.8M | 207.1M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FC | PLX |
|---|---|---|
| Price | $18.64 | $2.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.00 | N/A |
| AVG Volume (30 Days) | 37.4K | ★ 864.3K |
| Earning Date | 11-04-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $267,067,000.00 | $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | $4.19 | N/A |
| P/E Ratio | ★ N/A | $9.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $1.65 |
| 52 Week High | $26.81 | $3.19 |
Technical Indicators
Market Signals| Indicator | FC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 38.40 |
| Support Level | $18.75 | $2.21 |
| Resistance Level | $19.21 | $2.75 |
| Average True Range (ATR) | 0.68 | 0.10 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 79.48 | 8.82 |
Price Performance
Historical ComparisonAbout FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.